North America Rx dermatology topical drug delivery market is projected to register a healthy CAGR of 4.3% in the forecast period of 2019 to 2026. The new market report contains data for historic years 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Segmentation

By Product Type (Semi-Solid, Liquid, Solid), Application (Skin Infections, Dermatitis, Antiaging, Acne, Hyperpigmentation, Rosacea, Skin Cancer, Psoriasis, Onychomycosis, Others), Category (Branded, Generic), Country (U.S., Canada, Mexico)


Major growing sectors under the market segmentation are as follows:


? In product type, the semi-solid formulations is dominating the market as they are present in various forms such as ointments, creams, gel, paste and others. It is highly demanded as the semi-solid has more stability than other type.
? On the basis of application, skin infections are dominating the market due to various novel infections or diseases are present worldwide. Skin infections may be mild or serious and may require precise medical treatment. According to the study of BMC Infectious Diseases in 2013, there were 376,262 individuals' experienced 471,550 skin and soft tissue infections (SSTIs) episodes.
? In the category, the branded drugs are dominating the market due to the consumers demand for the branded drugs over the generic drugs. In the near future, the generic brands are growing as the branded drugs have their patent expirations and lower prices of generics are proving most affordable and decisive factor for selecting a generic product.

Market Players

The key market players for North America Rx dermatology topical drug delivery market are listed below:

? Galderma Laboratories, L.P.
? Hisamitsu Pharmaceutical Co., Inc.
? Pfizer Inc.
? LEO Pharma A/S
? GlaxoSmithKline plc.
? ALLERGAN
? Bayer AG
? 3M
? Bausch Health Companies Inc.
? The Lubrizol Corporation
? Cipla Inc.
? Kaken Pharmaceutical Co., Ltd.
? Others